Adjuvant Study of high-risk Muscle Invasive Urothelial Carcinoma Open-label, multicenter, randomized Phase III Study with Atezolizumab (Anti-PD-L1 Antibody) as adjuvant Therapy compared with Observation in Patients with high-risk Muscle Invasive Urothelial Carcinoma after Surgical Resection (IMvigor010) Study AB 53/15 of the AUO

被引：0
|
作者：
Rexer, H. [1 ]
Retz, M. [2 ]
Albers, P. [3 ]
机构：
[1] MeckEvidence, AUO Geschaftsstelle, Seestr 11, D-17252 Schwarz, Germany
[2] Tech Univ Munich, Klinikum Rechts Isar, Urol Klin & Poliklin, Munich, Germany
[3] Univ Klinikum Dusseldorf, Urol Klin, Dusseldorf, Germany
来源：
UROLOGE | 2016年 / 55卷 / 11期
关键词：
D O I：
10.1007/s00120-016-0248-5
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：1491 / 1493
页数：3
相关论文
共 50 条
  • [21] Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 CheckMate 274 trial
    Tomita, Yoshihiko
    Kobayashi, Ko
    Kimura, Go
    Oya, Mototsugu
    Uemura, Hirotsugu
    Nishiyama, Hiroyuki
    Galsky, Matthew D.
    Nasroulah, Federico
    Collette, Sandra
    Broughton, Edward
    Unsal-Kacmaz, Keziban
    Kamisuki, Yukinori
    Bajorin, Dean F.
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2023, 53 (01) : 16 - 25
  • [22] TRUCE-02: An open label, single-arm, phase II study of tislelizumab combined with nab-paclitaxel for high-risk non-muscle-invasive urothelial bladder carcinoma.
    Wang, HaiTao
    Hu, Hailong
    Niu, Yuanjie
    Tian, Dawei
    Shen, Chong
    Da, La
    Wu, Zhouliang
    Zhao, Gangjian
    Zhou, Diansheng
    Bai, Yiduo
    Chen, Houyuan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] Health-related quality of life with adjuvant nivolumab vs. placebo after radical resection for high-risk muscle-invasive urothelial carcinoma: Results from the phase 3 checkmate 274 trial
    Gschwend, J. E.
    Bajorin, D.
    Galsky, M.
    Broughton, E.
    Braverman, J.
    Koon, H.
    Maira-Arce, M.
    Hamilton, M.
    Shi, L.
    Guo, S.
    Witjes, J. A.
    EUROPEAN UROLOGY, 2021, 79 : S1139 - S1140
  • [24] Adjuvant therapy with donafenib plus anti-PD-1 antibody for patients (pts) with hepatocellular carcinoma (HCC) at high risk of recurrence after resection (PATH study)
    Chen, Yiwen
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Gao, Shunliang
    Que, Risheng
    Yu, Jun
    Tang, Xiaofeng
    Bai, Xueli
    Liang, Tingbo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [25] A pilot pre-surgical study evaluating anti-PD-L1 durvalumab (durva) plus anti-CTLA-4 tremelimumab (treme) in patients with muscle-Invasive, high-risk urothelial bladder carcinoma who are ineligible for cisplatin-based neoadjuvant chemotherapy.
    Gao, Jianjun
    Siefker-Radtke, Arlene O.
    Navai, Neema
    Campbell, Matthew T.
    Slack, Rebecca
    Guo, Charles
    Kamat, Ashish M.
    Matin, Surena F.
    Papadopoulos, John N.
    Araujo, John C.
    Shah, Amishi Yogesh
    Blando, Jorge M.
    Vence, Luis M.
    Duan, Fei
    Basu, Sreyashi
    Singh, Shalini
    Zhao, Hao
    Dinney, Colin P. N.
    Sharma, Padmanee
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Predictive Factors for Time to Progression after Hyperthermic Mitomycin C Treatment for High-Risk Non-Muscle Invasive Urothelial Carcinoma of the Bladder: An Observational Cohort Study of 97 Patients
    Sooriakumaran, Prasanna
    Chiocchia, Virginia
    Dutton, Susan
    Pai, Aakash
    Ayres, Benjamin E.
    Le Roux, Pieter
    Swinn, Michael
    Bailey, Michael
    Perry, Matthew J. A.
    Issa, Rami
    UROLOGIA INTERNATIONALIS, 2016, 96 (01) : 83 - 90
  • [27] A phase III study of atezolizumab (atezo) vs placebo as adjuvant therapy in renal cell carcinoma (RCC) patients (pts) at high risk of recurrence following resection (IMmotion010)
    Uzzo, Robert
    Bex, Axel
    Rini, Brian I.
    Albiges, Laurence
    Suarez, Cristina
    Donaldson, Frank
    Asakawa, Takashi
    Schiff, Christina
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] First results from the phase 3 CheckMate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma (MIUC).
    Bajorin, Dean F.
    Witjes, Johannes Alfred
    Gschwend, Jurgen
    Schenker, Michael
    Valderrama, Begona P.
    Tomita, Yoshihiko
    Bamias, Aristotelis
    Lebret, Thierry
    Shariat, Shahrokh
    Park, Se Hoon
    Ye Dingwei
    Agerbaek, Mads
    Collette, Sandra
    Unsal-Kacmaz, Keziban
    Zardavas, Dimitrios
    Koon, Henry B.
    Galsky, Matt D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [29] Tislelizumab plus sitravatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgical resection: Preliminary analysis of a multi-center, non-randomized, open-label phase 2 study
    Wang, Jiabei
    Peng, Tao
    Liu, Chang
    Zhang, Ling
    Zhu, Guangzhi
    Zhang, Xiaogang
    Wang, Xiaoqian
    Liu, Lianxin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [30] The efficacy and safety study of thymosin a1 combined with PD-1 antibodies as adjuvant therapy in patients with hepatocellular carcinoma with high-risk recurrence factors after radical resection
    Zhu RongHua
    Huang Zhiyong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345